USPTO serial 97081506
TETRAX
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- LE, KHANH M
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with TETRAX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Melissa A. Nowak, Reg. No. 68,088
MELISSA A. NOWAK, REG. NO. 68,088 CHRISTENSEN O'CONNOR JOHNSON KINDNESS1201 THIRD AVENUE, SUITE 3600SEATTLE, WA 98101UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | biochemicals, namely, antibody-derived antigen binding molecules and antibody-derived recombinant antigen binding molecules for in vitro scientific or research use | ACTIVE | — |
| 005 | pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical products for the diagnosis, prevention and treatment of cancer; Antibodies being pharmaceutical preparations for the diagnosis, treatment and prevention of cancer, immune response disorders, genetic conditions, infectious diseases and vascular diseases; Vaccines; Pharmaceutical preparations for cell therapy; Preparations of blood extracted from humans or animals which have been adapted for medical or therapeutic purposes | ACTIVE | — |
| 040 | custom manufacture of therapeutic drugs, namely, custom manufacture of cell therapies and cancer therapies; Manufacture of pharmaceuticals, pharmaceutical ingredients, vaccines and antibodies for others | ACTIVE | — |
| 042 | custom design and engineering of antibody-derived antigen binding molecules and antibody-derived recombinant antigen binding molecules; Providing a bioinformatics platform as a service (PAAS) featuring computer software for developing antibody-derived antigen binding molecules and antibody-derived recombinant antigen binding molecules; Custom design and engineering of antibodies; Custom design and engineering of antigens; Antibody engineering; Biochemical research and development; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Development and establishment of testing specifications and procedures in the field of biotechnology; Research and development in the pharmaceutical and biotechnology fields; Scientific research in the development of new cancer therapies; Scientific research in human and animal cell therapy; Platform as a service (PAAS) featuring computer software platforms for analysis of bioinformatic data | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SYNERGY IMT, INC.
- Other trademarks owned by SYNERGY IMT, INC.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named TETRAX
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 16, 2024 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jan 15, 2024 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 13, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 18, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 18, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 29, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 13, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 8, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 8, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 8, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 8, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 1, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 1, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 1, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 26, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 5, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 22, 2021 | NWAP | NEW APPLICATION ENTERED | — |